Thymosin Beta-4 is the full-length 43-amino acid protein from which the popular research peptide TB-500 is derived. While TB-500 fragments capture some of Tβ4’s activity, the full molecule has additional functions related to actin sequestration, gene regulation, and stem cell biology. It is one of the most extensively studied regenerative proteins in preclinical and early clinical development.
Dosage Information (Research Use)
Animal research: 6-150 μg per dose depending on model. Topical (corneal): 0.01-0.1% solution. Clinical trials used various routes. Investigational — not commercially available as a therapeutic.
Reconstitution & Handling
Reconstitute lyophilized powder in sterile water or saline.
Half-Life & Pharmacokinetics
~2-3 hours (estimated)
Reported Observations in Literature
Generally well tolerated in clinical trials. Topical formulations show minimal adverse events. Systemic administration safety profile similar to TB-500. Theoretical concern about promoting growth of existing cancers (angiogenesis).
Key Research References
- Goldstein AL et al. “Thymosin β4: a multi-functional regenerative peptide.” Expert Opin Biol Ther. 2012;12:37-51
- Dunn SP et al. “Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin β4.” Ann N Y Acad Sci. 2010;1194:199-206